Effecacy of anti-platelet drugs after endovascular therapy in patients with femoropopliteal artery disease.

Effecacy of anti-platelet drugs after endovascular therapy in patients with femoropopliteal artery disease. - Effecacy of anti-platelet drugs after EVT for femoropopliteal artery disease.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001880

Enrollment

Registered

2009-04-13

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peripheral artery disease

Interventions

sarpogrelate 100mgx3/day, 24weeks cilostazol 100mgx3/day, 24weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with successful endovascular therapy for femoropopliteal artery disease (lesional pressure gradient less than 20mmHg or residual percent diameter stenosis less than 50%)

Exclusion criteria

Exclusion criteria: Patients with bleeding tendency or congestive heart failure, or pregnant female.

Design outcomes

Primary

Measure	Time frame
percent diameter stenosis of the target lesion on angiography	—

Countries

Japan

Contacts

Public ContactSatoru Hirono

Niigata University Graduate School of Medical and Dental Sciences Division of Cardiology

hirono@med.niigata-u.ac.jp025-227-2185

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026